The cluster is heavily weighted by a single director's large sale, which could be diversification or a negative signal. Watch for any 8-K or press release in the next 2-4 weeks that might explain the selling—particularly clinical trial updates or partnership news, given MLYS is a clinical-stage biotech.
Price Chart
Executive Summary
Three insiders at Mineralys Therapeutics sold a total of $3.30M in stock over a one-week window, led by director Brian Taylor Slingsby's $3.01M open-market sale. The cluster is dominated by selling with no offsetting open-market purchases, and the total value represents approximately 1.0% of the company's $326M market cap, crossing the 0.5% threshold for significance.
Key Financial Metrics
Key Facts
- Three insiders sold shares totaling $3.30M in a 7-day window (Sept 15–22, 2026).
- Director Brian Taylor Slingsby sold 104,300 shares for $3.01M on Sept 22.
- CCO Eric Warren sold 7,438 shares for $209K on Sept 21 (same-day derivative exercise).
- Director Daphne Karydas sold 3,000 shares for $86K on Sept 15.
- Total selling value is ~1.0% of MLYS's $326M market cap.
- No open-market purchases were reported in the cluster.
Financial Impact
Total insider selling of $3.30M represents ~1.0% of market cap, a significant proportion for a single cluster.
Risk Factors
- Insider selling at this magnitude may indicate lack of confidence in near-term catalysts.
- No offsetting purchases suggest no insider conviction in current valuation.
- Clinical-stage biotech is binary-risk; insider sales ahead of data readouts can be a red flag.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MLYS-1790301017478 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 3 | $21.10 | awaiting T+20 | — | $21.13 (+0.14%) |
Oct 20, 2026 7d ago | 3 | $21.10 | awaiting T+20 | — | $21.13 (+0.14%) |
Oct 19, 2026 8d ago | 8-K | $21.58 | awaiting T+20 | — | $21.13 (−2.09%) |
Oct 13, 2026 14d ago | 144 | $20.76 | awaiting T+20 | — | $21.13 (+1.78%) |
Sep 30, 2026 27d ago | 144 | $23.72 | awaiting T+20 | — | $21.13 (−10.92%) |
Sep 29, 2026 28d ago | Press Release | $25.13 | awaiting T+20 | — | $21.13 (−15.92%) |
Sep 24, 2026 4w ago | Insider Cluster | $25.86 $20.55 | ▲ +20.53% | ▲ +19.06% | $21.13 (+18.29%) |
Sep 22, 2026 4w ago | Insider Cluster | $26.89 $21.10 | ▼ −21.53% | ▼ −22.22% | $21.13 (−21.42%) |
Aug 12, 2026 10w ago | 3 | $26.09 $28.20 | ▲ +8.09% | ▲ +9.83% | $21.13 (−19.01%) |
Jul 23, 2026 13w ago | Insider Cluster | $26.71 $25.65 | ▼ −3.97% | ▼ −7.59% | $21.13 (−20.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers